WO2005003296A3 - Albumin fusion proteins - Google Patents

Albumin fusion proteins Download PDF

Info

Publication number
WO2005003296A3
WO2005003296A3 PCT/US2004/001369 US2004001369W WO2005003296A3 WO 2005003296 A3 WO2005003296 A3 WO 2005003296A3 US 2004001369 W US2004001369 W US 2004001369W WO 2005003296 A3 WO2005003296 A3 WO 2005003296A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
albumin fusion
nucleic acids
vectors
host cells
Prior art date
Application number
PCT/US2004/001369
Other languages
French (fr)
Other versions
WO2005003296A2 (en
Inventor
William A Haseltine
Craig A Rosen
Original Assignee
Human Genome Sciences Inc
William A Haseltine
Craig A Rosen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, William A Haseltine, Craig A Rosen filed Critical Human Genome Sciences Inc
Priority to EP04785757A priority Critical patent/EP1594530A4/en
Priority to CA2513213A priority patent/CA2513213C/en
Publication of WO2005003296A2 publication Critical patent/WO2005003296A2/en
Priority to KR1020127015659A priority patent/KR101271635B1/en
Publication of WO2005003296A3 publication Critical patent/WO2005003296A3/en
Priority to US11/175,690 priority patent/US7521424B2/en
Priority to US11/495,624 priority patent/US20080004206A1/en
Priority to US11/932,823 priority patent/US20080194481A1/en
Priority to US12/426,882 priority patent/US20100048472A1/en
Priority to US12/793,652 priority patent/US20100291033A1/en
Priority to US12/793,658 priority patent/US8287859B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.
PCT/US2004/001369 2001-12-21 2004-01-20 Albumin fusion proteins WO2005003296A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP04785757A EP1594530A4 (en) 2003-01-22 2004-01-20 Albumin fusion proteins
CA2513213A CA2513213C (en) 2003-01-22 2004-01-20 Albumin fusion proteins
KR1020127015659A KR101271635B1 (en) 2001-12-21 2005-02-09 Albumin fusion proteins
US11/175,690 US7521424B2 (en) 2003-01-22 2005-07-07 Albumin fusion proteins
US11/495,624 US20080004206A1 (en) 2001-12-21 2006-07-31 Albumin fusion proteins
US11/932,823 US20080194481A1 (en) 2001-12-21 2007-10-31 Albumin Fusion Proteins
US12/426,882 US20100048472A1 (en) 2003-01-22 2009-04-20 Albumin Fusion Proteins
US12/793,652 US20100291033A1 (en) 2001-12-21 2010-06-03 Albumin Fusion Proteins
US12/793,658 US8287859B2 (en) 2001-12-21 2010-06-03 Methods of reducing toxicity and effects of cocaine by administering a butyrylcholinesterase (BChE)-albumin fusion protein

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US44130503P 2003-01-22 2003-01-22
US60/441,305 2003-01-22
US45320103P 2003-03-11 2003-03-11
US60/453,201 2003-03-11
US46722203P 2003-05-02 2003-05-02
US60/467,222 2003-05-02
US47281603P 2003-05-23 2003-05-23
US60/472,816 2003-05-23
US47626703P 2003-06-06 2003-06-06
US60/476,267 2003-06-06
US50517203P 2003-09-24 2003-09-24
US60/505,172 2003-09-24
US50674603P 2003-09-30 2003-09-30
US60/506,746 2003-09-30

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US11/714,841 Continuation-In-Part US20070244047A1 (en) 2001-12-21 2007-03-07 Albumin fusion proteins
US11/929,714 Continuation-In-Part US20080161243A1 (en) 2001-12-21 2007-10-30 Albumin Fusion Proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/175,690 Continuation US7521424B2 (en) 2001-12-21 2005-07-07 Albumin fusion proteins

Publications (2)

Publication Number Publication Date
WO2005003296A2 WO2005003296A2 (en) 2005-01-13
WO2005003296A3 true WO2005003296A3 (en) 2005-04-21

Family

ID=33569028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/001369 WO2005003296A2 (en) 2001-12-21 2004-01-20 Albumin fusion proteins

Country Status (4)

Country Link
US (2) US7521424B2 (en)
EP (1) EP1594530A4 (en)
CA (1) CA2513213C (en)
WO (1) WO2005003296A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993517B2 (en) 2001-12-21 2015-03-31 Human Genome Sciences, Inc. Albumin fusion proteins

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AU2001264563A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
KR101271635B1 (en) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
US20040248262A1 (en) 2003-01-22 2004-12-09 Koeberl Dwight D. Constructs for expressing lysomal polypeptides
WO2004096113A2 (en) * 2003-04-28 2004-11-11 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
PL1729795T3 (en) 2004-02-09 2016-08-31 Human Genome Sciences Inc Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
EP1841796A2 (en) 2004-12-02 2007-10-10 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
KR20080071119A (en) * 2005-08-12 2008-08-01 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
HUE029798T2 (en) 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods for administering hypoglycemic agents
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP1991574B1 (en) * 2006-02-22 2016-10-12 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
MX2008013119A (en) 2006-04-11 2008-10-21 Novartis Ag Hcv/hiv inhibitors an their uses.
US9222728B2 (en) * 2006-04-24 2015-12-29 Medinstill Development Llc Penetrable and resealable lyophilization device
WO2007146038A2 (en) * 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
WO2007144685A1 (en) * 2006-06-13 2007-12-21 Commissariat A L'energie Atomique Cd4 mimic peptides and their uses
FR2904627B1 (en) * 2006-08-04 2008-11-07 Pasteur Institut NOVEL ACTIVE, PURIFIED AND ISOLATED PEPTIDES, CD4 RECEPTOR DERIVATIVES (MINI-CD4) AND THEIR PREPARATION PROCESS
WO2008021412A2 (en) * 2006-08-14 2008-02-21 Biorexis Pharmaceutical Corporation Interferon beta and transferrin fusion proteins
JO2945B1 (en) * 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods For Administering Long-lasting Hypoglycemic Agents.
EP2423220B1 (en) 2007-01-30 2015-04-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CN102046207B (en) 2008-03-31 2013-08-28 葛兰素集团有限公司 Drug fusions and conjugates
US8685895B2 (en) 2008-12-05 2014-04-01 Carolyn Enever Methods for selecting protease resistant polypeptides
PT2373681T (en) 2008-12-10 2017-04-11 Glaxosmithkline Llc Pharmaceutical compositions of albiglutide
EA023344B1 (en) * 2009-01-16 2016-05-31 Тева Фармасьютикал Индастриз Лтд. Method for treating or preventing neutropenia or leukopenia or decreasing the incidence of infection as manifested by febrile neutropenia
EP2396347B1 (en) 2009-02-11 2017-04-12 Albumedix A/S Albumin variants and conjugates
UY32514A (en) 2009-03-27 2010-10-29 Glaxo Group Ltd FUSIONS AND CONJUGATES OF AN INSULINOTROPIC DRUG AND dAb WITH SEMIVIDA IMPROVED SERIES
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
EP2424549B1 (en) * 2009-04-28 2014-04-23 Optmed, Inc. Compositions and methods for treating or preventing urolithiasis and conditions associated therewith
US8451450B2 (en) * 2009-09-14 2013-05-28 Bio-Rad Laboratories, Inc. Near real time optical phase conjugation
SG10201406063XA (en) 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
JP2013508425A (en) 2009-10-30 2013-03-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dosage treatment plan for HCV combination therapy including BI201335, interferon alfa and ribavirin
BR112012009450A2 (en) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As albumin variants
CN102711795A (en) 2009-12-08 2012-10-03 泰华制药工业有限公司 BChE albumin fusions for the treatment of cocaine abuse
KR20130070576A (en) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 Albumin derivatives and variants
EP2566502A4 (en) 2010-05-04 2013-10-09 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
EP2586865B1 (en) * 2010-06-24 2018-03-21 Genomictree, Inc. Recombinant vector for suppressing proliferation of human papillomavirus cell including adenylate cyclase activating polypeptide 1 (pituitary) gene and pharmaceutical composition for treating human papillomavirus
MX2013000242A (en) 2010-06-24 2014-04-14 Panmed Ltd Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent.
MX2013003945A (en) 2010-10-08 2013-06-05 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors.
WO2012116453A1 (en) 2011-03-03 2012-09-07 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
US8822417B2 (en) 2011-05-05 2014-09-02 Novozymes Biopharma DIC A/S Albumin variants
EP3878859B1 (en) 2011-06-10 2023-11-01 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
BR112013032375B1 (en) 2011-06-17 2022-09-20 Hanmi Science Co., Ltd CONJUGATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
US9962430B2 (en) 2012-02-15 2018-05-08 Chirhoclin, Inc. Methods for treating pain associated with chronic pancreatitis
JP2015509980A (en) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy to treat HCV infection in a population of HCV-HIV co-infected patients
JP6441682B2 (en) 2012-03-16 2018-12-19 アルブミディクス リミティド Albumin variant
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
US20150342897A1 (en) 2012-05-16 2015-12-03 Glaxo Group Limited Polypeptide loaded poca nanoparticles for oral administration
US11406718B2 (en) 2012-05-29 2022-08-09 Chirhoclin, Inc. Methods of detecting pancreobiliary ductal leaks
AU2013289881B2 (en) 2012-07-13 2018-01-18 Zymeworks Bc Inc. Multivalent heteromultimer scaffold design and constructs
KR101968344B1 (en) 2012-07-25 2019-04-12 한미약품 주식회사 A composition for treating hyperlipidemia comprising oxyntomodulin analog
KR101993393B1 (en) 2012-11-06 2019-10-01 한미약품 주식회사 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
MY168536A (en) 2012-11-06 2018-11-12 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin fc region
MX2015005363A (en) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Albumin variants.
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2014125082A1 (en) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
RU2016103373A (en) 2013-07-04 2017-08-10 Новартис Аг CELLS OF FILMED MUSHROOMS WITH O-MANNOZYLTRANSPHERASE DEFICIENCY AND METHODS OF APPLICATION
EP3035950A4 (en) * 2013-08-14 2017-05-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
EP3137899A2 (en) 2014-05-02 2017-03-08 Cerenis Therapeutics Holding SA Hdl therapy markers
US10513724B2 (en) 2014-07-21 2019-12-24 Glykos Finland Oy Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
TWI772252B (en) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
CN105753990B (en) * 2014-12-19 2018-07-03 兰州大学 A kind of fusion protein of vasoactive intestinal peptide and its preparation method and application
KR102418477B1 (en) 2014-12-30 2022-07-08 한미약품 주식회사 Gluagon Derivatives
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
EP3526242A1 (en) 2016-10-12 2019-08-21 University of Copenhagen Peptide dual agonists of gipr and glp2r
CN110337590A (en) 2016-11-04 2019-10-15 奥胡斯大学 The identification and treatment of tumour characterized by neonatal Fc receptor is overexpressed
CN110461880A (en) * 2016-11-10 2019-11-15 科乐斯疗法公司 GDNF fused polypeptide and its application method
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN108727486A (en) * 2017-04-24 2018-11-02 舒泰神（北京）生物制药股份有限公司 Long-acting nerve growth factor, preparation method and combinations thereof
CN110183536B (en) * 2018-02-22 2021-01-15 中国科学院遗传与发育生物学研究所 Composite stent material and application thereof
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
CN113677800A (en) * 2018-11-13 2021-11-19 索元生物医药(美国)有限公司 Recombinant vector comprising a gene for a binding domain and a secretable peptide
US11744878B2 (en) 2020-08-19 2023-09-05 Chirhoclin, Inc. Methods for treatment of COVID-19 syndrome
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625041A (en) 1990-09-12 1997-04-29 Delta Biotechnology Limited Purification of proteins
DE2449885C3 (en) 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Process for the production of chemically modified, long-life hemoglobin preparations as well as the modified hemoglobin preparation produced by this process
US4363877B1 (en) 1977-09-23 1998-05-26 Univ California Recombinant dna transfer vectors
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4264731A (en) 1977-05-27 1981-04-28 The Regents Of The University Of California DNA Joining method
US4283489A (en) 1977-09-23 1981-08-11 The Regents Of The University Of California Purification of nucleotide sequences suitable for expression in bacteria
US4407948A (en) 1977-09-23 1983-10-04 The Regents Of The University Of California Purification of nucleotide sequences suitable for expression in bacteria
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4447538A (en) 1978-04-19 1984-05-08 Regents Of The University Of California Microorganism containing gene for human chorionic somatomammotropin
US4652525A (en) 1978-04-19 1987-03-24 The Regents Of The University Of California Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
FR2490675B1 (en) 1980-09-25 1985-11-15 Genentech Inc MICROBIAL PRODUCTION OF HUMAN FIBROPLASTER INTERFERON
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57149228A (en) 1981-03-11 1982-09-14 Ajinomoto Co Inc Novel erythropoietin and its preparation
US4792602A (en) 1981-06-19 1988-12-20 Cornell Research Foundation, Inc. Adaptors, and synthesis and cloning of proinsulin genes
US4450103A (en) 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4778879A (en) 1982-04-20 1988-10-18 Sloan-Kettering Institute For Cancer Research Highly purified human interleukin 2 and method
US4925919A (en) 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US4499188A (en) 1982-05-05 1985-02-12 Cetus Corporation Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US4462940A (en) 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4840934A (en) 1983-01-25 1989-06-20 Eleanor Roosevelt Institute For Cancer Research, Inc. Therapeutic method using T cell growth factor
US4914026A (en) 1983-04-07 1990-04-03 Chiron Corporation Alpha factor leader sequence directed secretion of insulin
US5015575A (en) 1983-04-07 1991-05-14 Chiron Corporation Hybrid DNA synthesis of insulin
US5010003A (en) 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
CA1196863A (en) 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4908433A (en) 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4908434A (en) 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
DK58285D0 (en) 1984-05-30 1985-02-08 Novo Industri As PEPTIDES AND MANUFACTURING AND USING THEREOF
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
GB8504099D0 (en) 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
FR2579224B1 (en) 1985-03-25 1987-05-22 Genetica PROCESS FOR THE MICROBIOLOGICAL PREPARATION OF HUMAN SERUM-ALBUMIN
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US5102872A (en) 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5641663A (en) 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
FR2594846B1 (en) 1986-02-21 1989-10-20 Genetica PROCESS FOR THE PREPARATION OF MATURE HUMAN ALBUMIN SERUM
DK179286D0 (en) 1986-04-18 1986-04-18 Nordisk Gentofte INSULIN PREPARATION
US4765980A (en) 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
US5028422A (en) 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
IT1196484B (en) 1986-07-11 1988-11-16 Sclavo Spa YEAST EXPRESSION AND SECRETION VECTOR, USEFUL FOR THE PREPARATION OF HETEROLOGICAL PROTEINS
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5002764A (en) 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
US4929442A (en) 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5508031A (en) 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US4835260A (en) 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
BR8806573A (en) 1987-04-09 1989-10-31 Delta Biotechnology Ltd LIGHT VECTOR
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JP2791418B2 (en) 1987-12-02 1998-08-27 株式会社ミドリ十字 Method for producing heterologous protein, recombinant DNA, transformant
JPH01240191A (en) 1988-02-16 1989-09-25 Green Cross Corp:The Novel signal peptide functioning by yeast and secretory manifestation of foreign protein using same
US4999339A (en) 1988-03-28 1991-03-12 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5066489A (en) 1988-03-28 1991-11-19 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5061488A (en) 1988-04-15 1991-10-29 The United States Of America As Represented Department Of Health & Human Services Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5096707A (en) 1988-04-15 1992-03-17 The United States Of America As Represented By The Department Of Health And Human Services Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
US5126129A (en) 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
ATE135045T1 (en) 1988-07-23 1996-03-15 Delta Biotechnology Ltd SECRETORY LEADER SEQUENCES
US5260202A (en) 1988-09-07 1993-11-09 Delta Biotechnology Limited Fermentation method
US5256410A (en) 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
DK105489D0 (en) 1989-03-03 1989-03-03 Novo Nordisk As POLYPEPTIDE
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
ATE79763T1 (en) 1989-04-11 1992-09-15 Boehringer Ingelheim Int USE OF AT LEAST ONE CYTOKINE IN THE MANUFACTURE OF A MEDICATION FOR THE SYSTEMIC TREATMENT OF PRAENEOPLASTIC LESIONS.
ATE125869T1 (en) 1989-06-09 1995-08-15 Gropep Pty Ltd GROWTH HORMONE FUSION PROTEINS.
DE3924746A1 (en) 1989-07-26 1991-01-31 Behringwerke Ag ERTHROPOIETIN (EPO) PEPTIDES AND ANTIBODIES THEREFOR
FR2650598B1 (en) * 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
FR2653020B1 (en) 1989-10-17 1993-03-26 Roussel Uclaf USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEUKEMIA.
US5667986A (en) 1989-10-18 1997-09-16 Delta Biotechnology Limited Yeast promoter for expressing heterologous polypeptides
US5116944A (en) 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5208018A (en) 1990-03-19 1993-05-04 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
FR2660863B1 (en) 1990-04-17 1994-01-21 Roussel Uclaf USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PRIMITIVE CANCERS OF THE POWDER.
GB9013017D0 (en) 1990-06-11 1990-08-01 Mars Uk Ltd Compounds
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
US5071872A (en) 1990-08-14 1991-12-10 The Ohio State University Research Foundation Method for improving interleukin-2 activity using aci-reductone compounds
FR2668368B1 (en) 1990-10-30 1995-03-10 Roussel Uclaf USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MALIGNANT EPITHELIAL TUMORS.
US5272070A (en) 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
US5646012A (en) 1991-04-30 1997-07-08 Rhone-Poulenc Rorer S.A. Yeast promoter and use thereof
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
AU665599B2 (en) 1991-11-08 1996-01-11 Hemosol Inc. Hemoglobins as drug delivery agents
GB9200417D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
FR2686620B1 (en) 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa HUMAN SERUM-ALBUMIN, PREPARATION AND USE.
FR2686900B1 (en) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5230886A (en) 1992-03-18 1993-07-27 Trustees Of Boston University Tumor cell suppression
US5460954A (en) 1992-04-01 1995-10-24 Cheil Foods & Chemicals, Inc. Production of human proinsulin using a novel vector system
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US5521086A (en) 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
US5459031A (en) 1993-11-05 1995-10-17 Amgen Inc. Methods for controlling sialic acid derivatives in recombinant glycoproteins
US5629286A (en) 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
US5646113A (en) 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5639642A (en) 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US20020048571A1 (en) * 1999-07-19 2002-04-25 Jeno Gyuris Chimeric polypeptides of serum albumin and uses related thereto
AU2001264563A1 (en) * 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2484556A1 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1997829A1 (en) * 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20060122374A1 (en) * 2002-02-07 2006-06-08 Peter Mertins Albumin-fused anti-angiogenesis peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1594530A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993517B2 (en) 2001-12-21 2015-03-31 Human Genome Sciences, Inc. Albumin fusion proteins
US9221896B2 (en) 2001-12-21 2015-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
US9296809B2 (en) 2001-12-21 2016-03-29 Human Genome Sciences, Inc. Albumin fusion proteins

Also Published As

Publication number Publication date
EP1594530A4 (en) 2006-10-11
CA2513213C (en) 2013-07-30
US20060014254A1 (en) 2006-01-19
WO2005003296A2 (en) 2005-01-13
US20100048472A1 (en) 2010-02-25
CA2513213A1 (en) 2005-01-13
EP1594530A2 (en) 2005-11-16
US7521424B2 (en) 2009-04-21

Similar Documents

Publication Publication Date Title
WO2005003296A3 (en) Albumin fusion proteins
WO2005077042A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
WO2007021494A3 (en) Albumin fusion proteins
WO2001079444A3 (en) Albumin fusion proteins
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2003059934A3 (en) Albumin fusion proteins
WO2003030821A3 (en) Albumin fusion proteins
WO2006119987A3 (en) Recombinant n-glycosylated proteins from procaryotic cells
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2006017355A3 (en) Improved aprotinin variants
WO2001042474A3 (en) Interferon-like molecules and uses thereof
WO2002102316A3 (en) Histone deacetylase and methods of use thereof
WO1999001551A3 (en) Novel inhibitor of cellular proliferation
WO2002097046A3 (en) B7 related protein-2 molecules and uses thereof
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2005054286A3 (en) Interleukin-11 fusion proteins
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
WO2001036478A3 (en) Methods and compositions relating to bactericidal/permeability increasing factor-like polypeptides and polynucleotides
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO2004058949A3 (en) Wnt-1 inhibitory factor-1 (wif-1) molecules and uses thereof
WO2002044366A3 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11175690

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2513213

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004785757

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004785757

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11175690

Country of ref document: US